

# Cediranib

**Catalog No: tcsc0119**



## Available Sizes

---

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg

**Size:** 200mg

**Size:** 500mg



## Specifications

---

**CAS No:**

288383-20-0

**Formula:**

$C_{25}H_{27}FN_4O_3$

**Pathway:**

Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Autophagy

**Target:**

VEGFR;PDGFR;Autophagy

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 49$  mg/mL (108.77 mM)

**Alternative Names:**

AZD2171

**Observed Molecular Weight:**


450.51

**Product Description**

Cediranib maleate (AZD-2171 maleate) is a highly potent, orally available **VEGFR** tyrosine kinase inhibitor with **IC<sub>50</sub>**s of IC50 & Target: IC50: [1]

**In Vitro:** In human umbilical vein endothelial cells, Cediranib inhibits VEGF-stimulated proliferation and KDR phosphorylation with IC<sub>50</sub> values of 0.4 and 0.5 nM, respectively. In a fibroblast/endothelial cell coculture model of vessel sprouting, Cediranib also reduces vessel area, length, and branching at subnanomolar concentrations<sup>[1]</sup>.

**In Vivo:** Once-daily oral administration of Cediranib ablates experimental (VEGF-induced) angiogenesis and inhibits endochondral ossification in bone or corpora luteal development in ovary; physiologic processes that are highly dependent upon neovascularization. The growth of established human tumor xenografts (colon, lung, prostate, breast, and ovary) in athymic mice is inhibited dose-dependently by Cediranib, with chronic administration of 1.5 mg per kg per day producing statistically significant inhibition in all models. A histologic analysis of Calu-6 lung tumors treated with Cediranib reveals a reduction in microvessel density within 52 hours that becomes progressively greater with the duration of treatment. These changes are indicative of vascular regression within tumors<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!